Project Grant R21AR084036
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- Project Grant Summary Rutgers The State University of New Jersey, Robert Wood Johnson Health Sciences (RBHS)-School of Nursing received a $637,018 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded August 7, 2025, with completion targeted for June 30, 2030. The grant funds basic and translational research investigating the role of natural killer (NK)...
- Federal Project Grant Summary Award Overview Loyola University of Chicago's Health Sciences Campus received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 25, 2025, with a completion date of May 31, 2027. The research initiative focuses on developing novel antibodies targeting autoreactive B cells as a potential therapeutic intervention for systemic lupus...
- Federal Project Grant Award Summary Mayo Clinic received a $127,273 project grant award dated September 5, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project, extending through August 31, 2027, investigates the role of TFEB (a transcription factor) in regulating age-associated B cells (ABCs) and their contribution to systemic autoimmunity, with...
- This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...
- Federal Grant Award Summary Emory University received a $372,210 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 15, 2025, with completion targeted for August 31, 2029. The research project addresses pregnancy and cardiovascular health outcomes in women with systemic lupus erythematosus (SLE), a chronic autoimmune disease that...
- Federal Project Grant Award Summary This five-year Career Development Award, administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to elucidate the mechanisms by which retroelements contribute to systemic lupus erythematosus (SLE) autoimmunity. Awarded to Yale University on May 15, 2026, with a total obligation of $170,964.00 and a completion date...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- Grant Award Summary The University of Pittsburgh received a $499,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026, through March 31, 2031. This award supports investigator-initiated biomedical research focused on the genetic and functional dissection of tissue-infiltrating and age-associated B cells in murine lupus models. The research aims to identify...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $177,984 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective June 1, 2026 through May 31, 2031. The research project, titled "Intrarenal Complement Activation as a Marker of Kidney Injury and Treatment Response in Lupus Nephritis," will be conducted at...
THE EXPOSOME IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS: EXACT NETWORK PLANNING - PROJECT SUMMARY THIS IS AN EXPLORATORY DEVELOPMENTAL GRANT AIMED AT THE DESIGN, DEVELOPMENT, AND IMPLEMENTATION OF A FUTURE NATIONAL, INTERDISCIPLINARY, COLLABORATIVE, TEAM SCIENCE RESEARCH NETWORK THAT WILL ADVANCE THE STUDY OF THE EXPOSOME IN AUTOIMMUNE DISEASES (EXPOSOME IN AUTOIMMUNE DISEASES COLLABORATING TEAMS, EXACT). WE PROPOSE TO PLAN A STUDY OF THE EXPOSOME DURING THE PRE-CLINICAL PERIOD OF RHEUMATOID ARTHRITIS (RA) AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). WE ASSERT THAT IT IS IMPORTANT TO MEASURE THE EXPOSOME PRIOR TO THE DEVELOPMENT OF DISEASE TO ENSURE THAT WHAT WE ARE MEASURING PRECEDES THE DISEASE AND IS NOT A CONSEQUENCE OF THE DISEASE (WHICH MIGHT HAPPEN IF THE EXPOSOME WERE MEASURED IN DISEASED INDIVIDUALS). THIS WILL ALLOW US TO DRAW INFERENCE ABOUT THE TEMPORALITY AND POTENTIAL CAUSALITY OF EXPOSURES ON THE RISK OF RA AND SLE. THIS CAN BE ACCOMPLISHED USING PROSPECTIVE COHORTS OF AT-RISK INDIVIDUALS THAT ARE FOLLOWED FOR THE DEVELOPMENT OF CLINICAL DISEASE (IE CLASSIFIABLE RA AND SLE) WITH WHICH WE HAVE A LONG HISTORY OF WORKING. INVESTIGATORS AT THE UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS (NORRIS, HOLERS AND ABRAHAM) WILL WORK WITH INVESTIGATORS AT THE OKLAHOMA MEDICAL RESEARCH FOUNDATION (JAMES AND MUNROE) TO CONDUCT A LANDSCAPE ANALYSIS OF RELEVANT EXISTING 1) RESOURCES, POPULATIONS, DATABASES, REGISTRIES, REPOSITORIES AND CONSORTIA, 2) DATA ON RELEVANT EXPOSURES, 3) EXPOSOME LABORATORIES, AND 4) EXPOSOME ANALYTIC TECHNIQUES. THIS WILL PROVIDE A BACKGROUND THAT WE WILL USE TO PLAN ACTIVITIES FOR A NEW PROJECT TO STUDY THE EXPOSOME IN RA AND SLE. AS PART OF THE PLANNING PROCESS, WE WILL HOLD A SUMMIT OF EXPOSOME EXPERTS AND INVESTIGATORS WITH COHORTS/POPULATIONS OF INDIVIDUALS AT-RISK FOR RA AND SLE, TO DEVELOP AND EXPAND EXISTING RESEARCH COLLABORATIONS TO CONDUCT A PROSPECTIVE STUDY IN THE EXPOSOME OF THESE DISEASES. WE WILL USE OUR EXISTING NOVEL COHORTS OF AT-RISK INDIVIDUALS WHO HAVE BEEN FOLLOWED TO THE DEVELOPMENT OF CLASSIFIABLE RA AND SLE TO EXPLORE FEASIBILITY OF HARMONIZATION OF QUESTIONNAIRE AND BIOMARKER DATA AND CONDUCT SECONDARY DATA ANALYSIS TO SUPPORT THE HYPOTHESIS AND RESEARCH STRATEGY OF THE FUTURE EXACT NETWORK. WE WILL ENGAGE STAKEHOLDERS SUCH AS SCIENTIFIC OR PROFESSIONAL ASSOCIATIONS AND PATIENTS AND PATIENT-ADVOCATES IN THE AREAS OF RA AND SLE FOR BETTER TRANSLATION TO INFORM THE EXACT NETWORK RESEARCH AGENDA. THE OVERALL GOAL OF THIS PROPOSAL IS TO PLAN RESEARCH STRATEGIES AND DEVELOP PARTNERSHIPS, INFRASTRUCTURE, AND CAPABILITIES NEEDED TO ADDRESS THE MAJOR GOALS OF A FUTURE COLLABORATIVE EXACT NETWORK AND TO DEVELOP A RESEARCH FRAMEWORK AND STRATEGIES TO SUPPORT COORDINATION AMONG STUDIES, COLLABORATIVE RESEARCH PROJECTS, AND SITES. SPECIFIC AIM 1. TO CONDUCT A MULTIPRONGED APPROACH TO DETERMINE THE NEEDS AND CURRENTLY AVAILABLE RESOURCES TO PROSPECTIVELY AND EFFECTIVELY MEASURE THE EXPOSOME IN RA AND SLE (VIA A LANDSCAPE ANALYSIS). SPECIFIC AIM 2. TO DESIGN A PROSPECTIVE STUDY TO EXAMINE THE ROLE OF THE EXPOSOME IN THE ETIOLOGY OF RA AND SLE, WITH AN INTERDISCIPLINARY RESEARCH TEAM, RIGOROUS EXPOSOME MEASUREMENTS AND NOVEL ANALYTIC APPROACHES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $17.6k | 9/8/25 | ||
| Not listed | $394.2k | 8/26/25 | ||
| Not listed | $0 | 8/25/25 | ||
| Not listed | $449.0k | 9/19/23 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
FY24018001S | Oklahoma Medical Research Foundation | Project Grant R21AR084036 | $127.9k | 10/30/25 |